The estimated Net Worth of Roger S Newton is at least $6.54 Milione dollars as of 12 March 2019. Roger Newton owns over 25,000 units of Esperion Therapeutics stock worth over $954,783 and over the last 11 years Roger sold ESPR stock worth over $5,580,414.
Roger has made over 8 trades of the Esperion Therapeutics stock since 2013, according to the Form 4 filled with the SEC. Most recently Roger sold 25,000 units of ESPR stock worth $1,251,500 on 12 March 2019.
The largest trade Roger's ever made was buying 42,346 units of Esperion Therapeutics stock on 1 July 2013 worth over $592,844. On average, Roger trades about 12,643 units every 149 days since 2013. As of 12 March 2019 Roger still owns at least 548,726 units of Esperion Therapeutics stock.
You can see the complete history of Roger Newton stock trades at the bottom of the page.
Roger's mailing address filed with the SEC is C/O ESPERION THERAPEUTICS, INC., 46701 COMMERCE CENTER DRIVE, PLYMOUTH, MI, 48170.
Over the last 11 years, insiders at Esperion Therapeutics have traded over $197,978,412 worth of Esperion Therapeutics stock and bought 6,755,593 units worth $134,445,709 . The most active insiders traders include Patrick G Enright, Target N Vbb Biotech Ag Bio... e Nicole Vitullo. On average, Esperion Therapeutics executives and independent directors trade stock every 33 days with the average trade being worth of $145,621. The most recent stock trade was executed by Eric Warren on 19 August 2024, trading 211 units of ESPR stock currently worth $411.
esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.
Esperion Therapeutics executives and other stock owners filed with the SEC include: